The DOI matches its Crossref record; 175 of the 175 references it cites were found in a registry or an index.
Inhibition of Toll-Like Receptor Signaling as a Promising Therapy for Inflammatory Diseases: A Journey from Molecular to Nano Therapeutics
Open accessAbstract
The recognition of invading pathogens and endogenous molecules from damaged tissues by toll-like receptors (TLRs) triggers protective self-defense mechanisms. However, excessive TLR activation disrupts the immune homeostasis by sustained pro-inflammatory cytokines and chemokines production and consequently contributes to the development of many inflammatory and autoimmune diseases, such as systemic lupus erythematosus (SLE), infection-associated sepsis, atherosclerosis, and asthma. Therefore, inhibitors/antagonists targeting TLR signals may be beneficial to treat these disorders. In this article, we first briefly summarize the pathophysiological role of TLRs in the inflammatory diseases. We then focus on reviewing the current knowledge in both preclinical and clinical studies of various TLR antagonists/inhibitors for the prevention and treatment of inflammatory diseases. These compounds range from conventional small molecules to therapeutic biologics and nanodevices. In particular, nanodevices are emerging as a new class of potent TLR inhibitors for their unique properties in desired bio-distribution, sustained circulation, and preferred pharmacodynamic and pharmacokinetic profiles. More interestingly, the inhibitory activity of these nanodevices can be regulated through precise nano-functionalization, making them the next generation therapeutics or "nano-drugs." Although, significant efforts have been made in developing different kinds of new TLR inhibitors/antagonists, only limited numbers of them have undergone clinical trials, and none have been approved for clinical uses to date. Nevertheless, these findings and continuous studies of TLR inhibition highlight the pharmacological regulation of TLR signaling, especially on multiple TLR pathways, as future promising therapeutic strategy for various inflammatory and autoimmune diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MicroRNAs: Target Recognition and Regulatory Functions
Bartel, D. P. (2009) · Cell · doi:10.1016/j.cell.2009.01.002 · Cited by 20,068
The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors
Kawai, T., & Akira, S. (2010) · Nature Immunology · doi:10.1038/ni.1863 · Cited by 9,304
Akira, S., & Takeda, K. (2004) · Nature reviews. Immunology · doi:10.1038/nri1391 · Cited by 8,312
Principles of nanoparticle design for overcoming biological barriers to drug delivery
Blanco, E., Shen, H., & Ferrari, M. (2015) · Nature Biotechnology · doi:10.1038/nbt.3330 · Cited by 7,002
Takeda, K., Kaisho, T., & Akira, S. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141126 · Cited by 6,143
Taganov, K. D., Boldin, M. P., Chang, K.-J., & Baltimore, D. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605298103 · Cited by 4,317 · cited 1×
“MiR-146a was identified from a screen of LPS-responsive genes regulated by NF-κB; it was found to inhibit the translation of the TNF receptorassociated family 6 (TRAF6) and IRAK1, both of which are in the downstream pathway of TLR4 signaling (Taganov et al., 2006).”
BackgroundToll-like receptors in innate immunity
Takeda, K. (2004) · International Immunology · doi:10.1093/intimm/dxh186 · Cited by 3,328
Role of Adaptor TRIF in the MyD88-Independent Toll-Like Receptor Signaling Pathway
Yamamoto, M., Sato, S., Hemmi, H., Hoshino, K., Kaisho, T., Sanjo, H., Takeuchi, O., Sugiyama, M., Okabe, M., Takeda, K., et al. (2003) · Science · doi:10.1126/science.1087262 · Cited by 3,235
Toll-Like Receptor Signaling Pathways
Kawasaki, T., & Kawai, T. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00461 · Cited by 3,233
Pathogen Recognition and Inflammatory Signaling in Innate Immune Defenses
Mogensen, T. H. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00046-08 · Cited by 3,111
He, C., Hu, Y., Yin, L., Tang, C., & Yin, C. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.01.065 · Cited by 2,607
Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date
Bobo, D., Robinson, K. J., Islam, J., Thurecht, K. J., & Corrie, S. R. (2016) · Pharmaceutical Research · doi:10.1007/s11095-016-1958-5 · Cited by 2,586
The structural basis of lipopolysaccharide recognition by the TLR4–MD-2 complex
Park, B. S., Song, D. H., Kim, H. M., Choi, B.-S., Lee, H., & Lee, J.-O. (2009) · Nature · doi:10.1038/nature07830 · Cited by 2,428
MicroRNA-155 is induced during the macrophage inflammatory response
O'Connell, R. M., Taganov, K. D., Boldin, M. P., Cheng, G., & Baltimore, D. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0610731104 · Cited by 1,866
Bacterial endotoxin: molecular relationships of structure to activity and function
Rietschel, E. T., Kirikae, T., Schade, F. U., Mamat, U., Schmidt, G., Loppnow, H., Ulmer, A. J., Zähringer, U., Seydel, U., Di Padova, F., et al. (1994) · The FASEB Journal · doi:10.1096/fasebj.8.2.8119492 · Cited by 1,607
Therapeutic antibodies: successes, limitations and hopes for the future
Chames, P., Van Regenmortel, M., Weiss, E., & Baty, D. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00190.x · Cited by 1,382
Anselmo, A. C., & Mitragotri, S. (2016) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10003 · Cited by 1,321
Tili, E., Michaille, J.-J., Cimino, A., Costinean, S., Dumitru, C. D., Adair, B., Fabbri, M., Alder, H., Liu, C. G., Calin, G. A., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.8.5082 · Cited by 1,304
Itzkowitz, S. H., & Yio, X. (2004) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00079.2004 · Cited by 1,274
Toll-like receptors in systemic autoimmune disease
Marshak-Rothstein, A. (2006) · Nature Reviews Immunology · doi:10.1038/nri1957 · Cited by 1,116
Christensen, S. R., Shupe, J., Nickerson, K., Kashgarian, M., Flavell, R. A., & Shlomchik, M. J. (2006) · Immunity · doi:10.1016/j.immuni.2006.07.013 · Cited by 1,090
Michelsen, K. S., Wong, M. H., Shah, P. K., Zhang, W., Yano, J., Doherty, T. M., Akira, S., Rajavashisth, T. B., & Arditi, M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403249101 · Cited by 1,019
Ernsting, M. J., Murakami, M., Roy, A., & Li, S.-D. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.09.013 · Cited by 1,012
Sheedy, F. J., Palsson-McDermott, E., Hennessy, E. J., Martin, C., O'Leary, J. J., Ruan, Q., Johnson, D. S., Chen, Y., & O'Neill, L. A. J. (2010) · Nature Immunology · doi:10.1038/ni.1828 · Cited by 1,005
Ruiz-Irastorza, G., Ramos-Casals, M., Brito-Zeron, P., & Khamashta, M. A. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.101766 · Cited by 978
Barrat, F. J., Meeker, T., Gregorio, J., Chan, J. H., Uematsu, S., Akira, S., Chang, B., Duramad, O., & Coffman, R. L. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050914 · Cited by 928
Autoreactive B Cell Responses to RNA-Related Antigens Due to TLR7 Gene Duplication
Pisitkun, P., Deane, J. A., Difilippantonio, M. J., Tarasenko, T., Satterthwaite, A. B., & Bolland, S. (2006) · Science · doi:10.1126/science.1124978 · Cited by 894
MicroRNA-155 Promotes Autoimmune Inflammation by Enhancing Inflammatory T Cell Development
O'Connell, R. M., Kahn, D., Gibson, W. S. J., Round, J. L., Scholz, R. L., Chaudhuri, A. A., Kahn, M. E., Rao, D. S., & Baltimore, D. (2010) · Immunity · doi:10.1016/j.immuni.2010.09.009 · Cited by 889
Targeting Toll-like receptors: emerging therapeutics?
Hennessy, E. J., Parker, A. E., & O'Neill, L. A. J. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3203 · Cited by 886
miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice
Boldin, M. P., Taganov, K. D., Rao, D. S., Yang, L., Zhao, J. L., Kalwani, M., Garcia-Flores, Y., Luong, M., Devrekanli, A., Xu, J., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101823 · Cited by 861
Edfeldt, K., Swedenborg, J., Hansson, G. K., & Yan, Z.-Q. (2002) · PubMed · Cited by 847
Beutler, B. A. (2009) · Blood · doi:10.1182/blood-2008-07-019307 · Cited by 840
Assembly and localization of Toll-like receptor signalling complexes
Gay, N. J., Symmons, M. F., Gangloff, M., & Bryant, C. E. (2014) · Nature Reviews Immunology · doi:10.1038/nri3713 · Cited by 832
Opal, S. M., Laterre, P.-F., Francois, B., LaRosa, S. P., Angus, D. C., Mira, J.-P., Wittebole, X., Dugernier, T., Perrotin, D., Tidswell, M., et al. (2013) · JAMA · doi:10.1001/jama.2013.2194 · Cited by 812
Tang, Y., Luo, X., Cui, H., Ni, X., Yuan, M., Guo, Y., Huang, X., Zhou, H., de Vries, N., Tak, P. P., et al. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24436 · Cited by 735
Pattern recognition receptors and control of adaptive immunity
Palm, N. W., & Medzhitov, R. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00731.x · Cited by 729
Phase I and Pharmacokinetic Studies of CYT-6091, a Novel PEGylated Colloidal Gold-rhTNF Nanomedicine
Libutti, S. K., Paciotti, G. F., Byrnes, A. A., Alexander, H. R., Gannon, W. E., Walker, M., Seidel, G. D., Yuldasheva, N., & Tamarkin, L. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0978 · Cited by 710
Sato, S., Sugiyama, M., Yamamoto, M., Watanabe, Y., Kawai, T., Takeda, K., & Akira, S. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.8.4304 · Cited by 710
The Structural Biology of Toll-like Receptors
Botos, I., Segal, D. M., & Davies, D. R. (2011) · Structure · doi:10.1016/j.str.2011.02.004 · Cited by 693
A Tlr7 translocation accelerates systemic autoimmunity in murine lupus
Subramanian, S., Tus, K., Li, Q.-Z., Wang, A., Tian, X.-H., Zhou, J., Liang, C., Bartov, G., McDaniel, L. D., Zhou, X. J., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603912103 · Cited by 651
Self-citationCeppi, M., Pereira, P. M., Dunand-Sauthier, I., Barras, E., Reith, W., Santos, M. A., & Pierre, P. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811073106 · Cited by 631
Toll-Like Receptor-4 Promotes the Development of Colitis-Associated Colorectal Tumors
Fukata, M., Chen, A., Vamadevan, A. S., Cohen, J., Breglio, K., Krishnareddy, S., Hsu, D., Xu, R., Harpaz, N., Dannenberg, A. J., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.09.008 · Cited by 621
Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines
Kužnik, A., Benčina, M., Švajger, U., Jeras, M., Rozman, B., & Jerala, R. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1000702 · Cited by 606
Matsunaga, N., Tsuchimori, N., Matsumoto, T., & Ii, M. (2011) · Molecular Pharmacology · doi:10.1124/mol.110.068064 · Cited by 597
Modulation of atherosclerosis in mice by Toll-like receptor 2
Mullick, A. E. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25482 · Cited by 549
A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis*
Rice, T. W., Wheeler, A. P., Bernard, G. R., Vincent, J.-L., Angus, D. C., Aikawa, N., Demeyer, I., Sainati, S., Amlot, N., Cao, C., et al. (2010) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181e7c5c9 · Cited by 512
Moresco, E. M. Y., LaVine, D., & Beutler, B. (2011) · Current Biology · doi:10.1016/j.cub.2011.05.039 · Cited by 500
Toll-like Receptors and Type I Interferons
Uematsu, S., & Akira, S. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.r700009200 · Cited by 498
TLR3 is an endogenous sensor of tissue necrosis during acute inflammatory events
Cavassani, K. A., Ishii, M., Wen, H., Schaller, M. A., Lincoln, P. M., Lukacs, N. W., Hogaboam, C. M., & Kunkel, S. L. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20081370 · Cited by 449
Therapeutic Targeting of Toll-Like Receptors for Infectious and Inflammatory Diseases and Cancer
O’Neill, L. A. J., Bryant, C. E., & Doyle, S. L. (2009) · Pharmacological Reviews · doi:10.1124/pr.109.001073 · Cited by 427
The TLR4 antagonist Eritoran protects mice from lethal influenza infection
Shirey, K. A., Lai, W., Scott, A. J., Lipsky, M., Mistry, P., Pletneva, L. M., Karp, C. L., McAlees, J., Gioannini, T. L., Weiss, J., et al. (2013) · Nature · doi:10.1038/nature12118 · Cited by 423
Gilliet, M., Conrad, C., Geiges, M., Cozzio, A., Thürlimann, W., Burg, G., Nestle, F. O., & Dummer, R. (2004) · Archives of Dermatology · doi:10.1001/archderm.140.12.1490 · Cited by 408
Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia.
Pajkrt, D., Doran, J. E., Koster, F., Lerch, P. G., Arnet, B., van der Poll, T., ten Cate, J. W., & van Deventer, S. J. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.5.1601 · Cited by 390
TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus
Guiducci, C., Gong, M., Xu, Z., Gill, M., Chaussabel, D., Meeker, T., Chan, J. H., Wright, T., Punaro, M., Bolland, S., et al. (2010) · Nature · doi:10.1038/nature09102 · Cited by 380
Nickerson, K. M., Christensen, S. R., Shupe, J., Kashgarian, M., Kim, D., Elkon, K., & Shlomchik, M. J. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902592 · Cited by 347
Toll‐like receptor 4 in CNS pathologies
Buchanan, M. M., Hutchinson, M., Watkins, L. R., & Yin, H. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06736.x · Cited by 336
Cancer Cells Expressing Toll-like Receptors and the Tumor Microenvironment
Sato, Y., Goto, Y., Narita, N., & Hoon, D. S. B. (2009) · Cancer Microenvironment · doi:10.1007/s12307-009-0022-y · Cited by 319
E5531, a Pure Endotoxin Antagonist of High Potency
Christ, W. J., Asano, O., Robidoux, A. L. C., Perez, M., Wang, Y., Dubuc, G. R., Gavin, W. E., Hawkins, L. D., McGuinness, P. D., Mullarkey, M. A., et al. (1995) · Science · doi:10.1126/science.7701344 · Cited by 318
Wang, L., Brown, J. R., Varki, A., & Esko, J. D. (2002) · Journal of Clinical Investigation · doi:10.1172/jci14996 · Cited by 314
A trio of microRNAs that control Toll-like receptor signalling
Quinn, S. R., & O'Neill, L. A. (2011) · International Immunology · doi:10.1093/intimm/dxr034 · Cited by 314
Mullarkey, M., Rose, J. R., Bristol, J., Kawata, T., Kimura, A., Kobayashi, S., Przetak, M., Chow, J., Gusovsky, F., Christ, W. J., et al. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.044487 · Cited by 292
Wang, L., Brown, J. R., Varki, A., & Esko, J. D. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0214996 · Cited by 288
Barrat, F. J., Meeker, T., Chan, J. H., Guiducci, C., & Coffman, R. L. (2007) · European Journal of Immunology · doi:10.1002/eji.200737815 · Cited by 284
Inhibition of Toll-like Receptor 4 With Eritoran Attenuates Myocardial Ischemia-Reperfusion Injury
Shimamoto, A., Chong, A. J., Yada, M., Shomura, S., Takayama, H., Fleisig, A. J., Agnew, M. L., Hampton, C. R., Rothnie, C. L., Spring, D. J., et al. (2006) · Circulation · doi:10.1161/circulationaha.105.000901 · Cited by 284
Houghton, J., & Wang, T. C. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.03.037 · Cited by 276
Protection from lethal Gram-negative bacterial sepsis by targeting Toll-like receptor 4
Roger, T., Froidevaux, C., Le Roy, D., Reymond, M. K., Chanson, A.-L., Mauri, D., Burns, K., Riederer, B. M., Akira, S., & Calandra, T. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808146106 · Cited by 269
Toll-like Receptors in the Vascular System: Sensing the Dangers Within
Goulopoulou, S., McCarthy, C. G., & Webb, R. C. (2016) · Pharmacological Reviews · doi:10.1124/pr.114.010090 · Cited by 263
The role of Toll-like receptors in chronic inflammation
Drexler, S. K., & Foxwell, B. M. (2010) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2009.10.009 · Cited by 248
Heparin in Inflammation: Potential Therapeutic Applications beyond Anticoagulation
Tyrrell, D. J., Horne, A. P., Holme, K. R., Preuss, J. M. H., & Page, C. P. (1999) · Advances in Pharmacology · doi:10.1016/s1054-3589(08)60471-8 · Cited by 245
The role of antimalarial agents in the treatment of SLE and lupus nephritis
Lee, S.-J., Silverman, E., & Bargman, J. M. (2011) · Nature Reviews Nephrology · doi:10.1038/nrneph.2011.150 · Cited by 241
ROLE OF TOLL-LIKE RECEPTORS IN THE DEVELOPMENT OF SEPSIS
Tsujimoto, H., Ono, S., Efron, P. A., Scumpia, P. O., Moldawer, L. L., & Mochizuki, H. (2008) · Shock · doi:10.1097/shk.0b013e318157ee55 · Cited by 239
MicroRNAs: New Regulators of Toll-Like Receptor Signalling Pathways
He, X., Jing, Z., & Cheng, G. (2014) · BioMed Research International · doi:10.1155/2014/945169 · Cited by 238
Tidswell, M., Tillis, W., LaRosa, S. P., Lynn, M., Wittek, A. E., Kao, R., Wheeler, J., Gogate, J., & Opal, S. M. (2010) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181b07b78 · Cited by 229
Droemann, D., Goldmann, T., Tiedje, T., Zabel, P., Dalhoff, K., & Schaaf, B. (2005) · Respiratory Research · doi:10.1186/1465-9921-6-68 · Cited by 224
TLR7-dependent and FcγR-independent production of type I interferon in experimental mouse lupus
Lee, P. Y., Kumagai, Y., Li, Y., Takeuchi, O., Yoshida, H., Weinstein, J., Kellner, E. S., Nacionales, D., Barker, T., Kelly-Scumpia, K., et al. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20080462 · Cited by 223
Mullick, A. E., Soldau, K., Kiosses, W. B., Bell, T. A., Tobias, P. S., & Curtiss, L. K. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20071096 · Cited by 223
Antagonistic antibody prevents toll-like receptor 2–driven lethal shock-like syndromes
Meng, G., Rutz, M., Schiemann, M., Metzger, J., Grabiec, A., Schwandner, R., Luppa, P. B., Ebel, F., Busch, D. H., Bauer, S., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420762 · Cited by 213
McCarthy, C. G., Wenceslau, C. F., Goulopoulou, S., Ogbi, S., Baban, B., Sullivan, J. C., Matsumoto, T., & Webb, R. C. (2015) · Cardiovascular Research · doi:10.1093/cvr/cvv137 · Cited by 193
Chloroquine and inhibition of Toll-like receptor 9 protect from sepsis-induced acute kidney injury
Yasuda, H., Leelahavanichkul, A., Tsunoda, S., Dear, J. W., Takahashi, Y., Ito, S., Hu, X., Zhou, H., Doi, K., Childs, R., et al. (2008) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00461.2007 · Cited by 192
Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial
Paton, N. I., Lee, L., Xu, Y., Ooi, E. E., Cheung, Y. B., Archuleta, S., Wong, G., & Smith, A. W. (2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70065-2 · Cited by 189
Loiarro, M., Capolunghi, F., Fantò, N., Gallo, G., Campo, S., Arseni, B., Carsetti, R., Carminati, P., De Santis, R., Ruggiero, V., et al. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.1206746 · Cited by 189
Long-term activation of TLR3 by Poly(I:C) induces inflammation and impairs lung function in mice
Stowell, N. C., Seideman, J., Raymond, H. A., Smalley, K. A., Lamb, R. J., Egenolf, D. D., Bugelski, P. J., Murray, L. A., Marsters, P. A., Bunting, R. A., et al. (2009) · Respiratory Research · doi:10.1186/1465-9921-10-43 · Cited by 185
McCarthy, C. G., Goulopoulou, S., Wenceslau, C. F., Spitler, K., Matsumoto, T., & Webb, R. C. (2014) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00328.2013 · Cited by 182
Denlinger, L. C., Fisette, P. L., Sommer, J. A., Watters, J. J., Prabhu, U., Dubyak, G. R., Proctor, R. A., & Bertics, P. J. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.4.1871 · Cited by 181
Role of Toll-like receptors in gastrointestinal malignancies
Fukata, M., & Abreu, M. T. (2008) · Oncogene · doi:10.1038/sj.onc.1210908 · Cited by 178
Komatsuda, A., Wakui, H., Iwamoto, K., Ozawa, M., Togashi, M., Masai, R., Maki, N., Hatakeyama, T., & Sawada, K. (2008) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2008.03646.x · Cited by 173
Statins Decrease Toll-Like Receptor 4 Expression and Downstream Signaling in Human CD14 + Monocytes
Methe, H., Kim, J.-O., Kofler, S., Nabauer, M., & Weis, M. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000168410.44722.86 · Cited by 172
Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies
Barochia, A., Solomon, S., Cui, X., Natanson, C., & Eichacker, P. Q. (2011) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2011.558190 · Cited by 169
Toll-like receptors: potential targets for lupus treatment
Wu, Y.-W., Tang, W., & Zuo, J.-P. (2015) · Acta Pharmacologica Sinica · doi:10.1038/aps.2015.91 · Cited by 168
Jackson, S. W., Scharping, N. E., Kolhatkar, N. S., Khim, S., Schwartz, M. A., Li, Q.-Z., Hudkins, K. L., Alpers, C. E., Liggitt, D., & Rawlings, D. J. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400098 · Cited by 165
Self-citationTGF-α Regulates TLR Expression and Function on Epidermal Keratinocytes
Miller, L. S., Sørensen, O. E., Liu, P. T., Jalian, H. R., Eshtiaghpour, D., Behmanesh, B. E., Chung, W., Starner, T. D., Kim, J., Sieling, P. A., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.10.6137 · Cited by 163
Toll-Like Receptor-2 Mediates Inflammation and Matrix Degradation in Human Atherosclerosis
Monaco, C., Gregan, S. M., Navin, T. J., Foxwell, B. M. J., Davies, A. H., & Feldmann, M. (2009) · Circulation · doi:10.1161/circulationaha.109.851881 · Cited by 162
Ungaro, R., Fukata, M., Hsu, D., Hernandez, Y., Breglio, K., Chen, A., Xu, R., Sotolongo, J., Espana, C., Zaias, J., et al. (2009) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.90496.2008 · Cited by 159
Wozniacka, A., Lesiak, A., Narbutt, J., McCauliffe, D. P., & Sysa-Jedrzejowska, A. (2006) · Lupus · doi:10.1191/0961203306lu2299oa · Cited by 158
Toll-like receptor-4 mediates cigarette smoke-induced cytokine production by human macrophages
Karimi, K., Sarir, H., Mortaz, E., Smit, J. J., Hosseini, H., de Kimpe, S. J., Nijkamp, F. P., & Folkerts, G. (2006) · Respiratory Research · doi:10.1186/1465-9921-7-66 · Cited by 154
Kono, D. H., Haraldsson, M. K., Lawson, B. R., Pollard, K. M., Koh, Y. T., Du, X., Arnold, C. N., Baccalà, R., Silverman, G. J., Beutler, B., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905441106 · Cited by 148
Dagvadorj, J., Shimada, K., Chen, S., Jones, H. D., Tumurkhuu, G., Zhang, W., Wawrowsky, K., Crother, T. R., & Arditi, M. (2015) · Immunity · doi:10.1016/j.immuni.2015.03.007 · Cited by 148
MicroRNAs—novel regulators of systemic lupus erythematosus pathogenesis
Shen, N., Liang, D., Tang, Y., de Vries, N., & Tak, P. P. (2012) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2012.142 · Cited by 143
Suzuki, M., Kato, C., & Kato, A. (2015) · Journal of Toxicologic Pathology · doi:10.1293/tox.2015-0031 · Cited by 141
Lartigue, A., Colliou, N., Calbo, S., François, A., Jacquot, S., Arnoult, C., Tron, F., Gilbert, D., & Musette, P. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803219 · Cited by 141
High Density Lipoprotein Protects against Polymicrobe-induced Sepsis in Mice*
Guo, L., Ai, J., Zheng, Z., Howatt, D. A., Daugherty, A., Huang, B., & Li, X. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.442699 · Cited by 141
Hernanz, R., Martínez‐Revelles, S., Palacios, R., Martín, Á., Cachofeiro, V., Aguado, A., García-Redondo, L., Barrús, M. T., de Batista, P. R., Briones, A. M., et al. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13117 · Cited by 140
TLR4 Up-Regulation at Protein or Gene Level Is Pathogenic for Lupus-Like Autoimmune Disease
Liu, B., Yang, Y., Dai, J., Medzhitov, R. M., Freudenberg, M. A., Zhang, P. L., & Li, Z. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.10.6880 · Cited by 140
Gómez‐Guzmán, M., Jiménez, R., Romero, M., Sánchez, M., Zarzuelo-Romero, M. J., Gómez‐Morales, M., O’Valle, F., López-Farré, A. J., Algieri, F., Gálvez, J., et al. (2014) · Hypertension · doi:10.1161/hypertensionaha.114.03587 · Cited by 137
Wang, L., Li, Y., Zhang, C., Cui, W., Xia, W., Xia, Y., Du, J., & Li, H. (2013) · Cardiovascular Research · doi:10.1093/cvr/cvt258 · Cited by 135
Toll-like receptors in cerebral ischemic inflammatory injury
Wang, Y., Lin, S., & Yang, Q. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-134 · Cited by 134
Targeting of Toll-like receptors: a decade of progress in combating infectious diseases
Hedayat, M., Netea, M. G., & Rezaei, N. (2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70099-8 · Cited by 132
Gold Nanotheranostics: Proof-of-Concept or Clinical Tool?
Pedrosa, P., Vinhas, R., Fernandes, A. R., & Baptista, P. V. (2015) · Nanomaterials · doi:10.3390/nano5041853 · Cited by 129
Role of Toll-Like Receptor 4 in Intimal Foam Cell Accumulation in Apolipoprotein E–Deficient Mice
Higashimori, M., Tatro, J. B., Moore, K. J., Mendelsohn, M. E., Galper, J., & Beasley, D. (2010) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.110.210971 · Cited by 128
INCREASED EXPRESSION OF TOLL-LIKE RECEPTOR-2 AND -4 ON LEUKOCYTES FROM PATIENTS WITH SEPSIS
rter, L. H., Mica, L., Stocker, R. A., Trentz, O., & Keel, M. J. B. (2004) · Shock · doi:10.1097/01.shk.0000142256.23382.5d · Cited by 124
Reilly, M., Miller, R. M., Thomson, M., Patris, V., Ryle, P. R., McLoughlin, L., Mutch, P. J., Gilboy, P., Miller, C., Broekema, M., et al. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.150 · Cited by 124
Hou, L., He, S., Li, X., Yang, Y., He, P., Zhou, Y., Zhu, F., Yang, Y., Li, Y., Tang, W., et al. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30392 · Cited by 122
Toll-Like Receptors and Ischemic Brain Injury
Gesuete, R., Kohama, S. G., & Stenzel‐Poore, M. P. (2014) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000068 · Cited by 121
TLR4/MD-2 Monoclonal Antibody Therapy Affords Protection in Experimental Models of Septic Shock
Daubeuf, B., Mathison, J. C., Spiller, S., Hugues, S., Herren, S., Ferlin, W. G., Kosco‐Vilbois, M. H., Wagner, H., Kirschning, C. J., Ulevitch, R. J., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.9.6107 · Cited by 121
TLR4-induced IFN-γ production increases TLR2 sensitivity and drives Gram-negative sepsis in mice
Spiller, S., Elson, G., Ferstl, R., Dreher, S., Mueller, T., Freudenberg, M. A., Daubeuf, B., Wagner, H., & Kirschning, C. J. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20071990 · Cited by 120
Merrill, J. T., & Lahita, R. G. (1996) · Lupus · doi:10.1177/096120339600500103 · Cited by 118
Arslan, F., Houtgraaf, J. H., Keogh, B., Kazemi, K., de Jong, R., McCormack, W. J., O'Neill, L. A. J., McGuirk, P., Timmers, L., Smeets, M. B., et al. (2012) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.111.967596 · Cited by 113
Dual Role of Toll-Like Receptors in Asthma and Chronic Obstructive Pulmonary Disease
Bezemer, G. F. G., Sagar, S., van Bergenhenegouwen, J., Georgiou, N., Garssen, J., Kraneveld, A. D., & Folkerts, G. (2012) · Pharmacological Reviews · doi:10.1124/pr.111.004622 · Cited by 110
Wu, Y., He, S., Bai, B., Zhang, L., Xue, L., Lin, Z., Yang, X., Zhu, F., He, P., Tang, W., et al. (2015) · Cellular and Molecular Immunology · doi:10.1038/cmi.2015.13 · Cited by 105
MS2 VLP-based delivery of microRNA-146a inhibits autoantibody production in lupus-prone mice
Pan, Y., Jia, Zhang, Zhang, Zhang, Li, & Wang, L. (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s37990 · Cited by 103
Li, N., Harkema, J. R., Lewandowski, R. P., Wang, M., Bramble, L. A., Gookin, G., Ning, Z., Kleinman, M. T., Sioutas, C., & Nel, A. E. (2010) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00115.2010 · Cited by 101
Suárez‐Fariñas, M., Arbeit, R. D., Jiang, W., Ortenzio, F. S., Sullivan, T., & Krueger, J. G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0084634 · Cited by 98
Farrar, C. A., Keogh, B., McCormack, W. J., O'Shaughnessy, A. M., Parker, A. E., Reilly, M., & Sacks, S. H. (2011) · The FASEB Journal · doi:10.1096/fj.11-195396 · Cited by 94
Candesartan inhibits Toll-like receptor expression and activity both in vitro and in vivo
Dasu, M. R. K., Riosvelasco, A. C., & Jialal, I. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.04.010 · Cited by 93
Lyn‐Cook, B. D., Xie, C., Oates, J. R., Treadwell, E. L., Word, B. R., Hammons, G., & Wiley, K. L. (2014) · Molecular Immunology · doi:10.1016/j.molimm.2014.05.001 · Cited by 93
Lee, Y. H., Choi, S. J., Ji, J. D., & Song, G. G. (2016) · Lupus · doi:10.1177/0961203315622823 · Cited by 93
Cigarette smoke induces CXCL8 production by human neutrophilsviaactivation of TLR9 receptor
Mortaz, E., Adcock, I. M., Ito, K., Kraneveld, A. D., Nijkamp, F. P., & Folkerts, G. (2009) · European Respiratory Journal · doi:10.1183/09031936.00062209 · Cited by 88
Yang, H. Y., Fung, S., Xu, S., Sutherland, D. P., Kollmann, T. R., Liu, M., & Turvey, S. E. (2015) · ACS Nano · doi:10.1021/nn505634h · Cited by 88
Self-citationUltaigh, S. N. A., Saber, T., McCormick, J., Connolly, M., Dellacasagrande, J., Keogh, B., McCormack, W. J., Reilly, M., O'Neill, L. A. J., McGuirk, P., et al. (2011) · Arthritis Research & Therapy · doi:10.1186/ar3261 · Cited by 86
Capolunghi, F., Rosado, M. M., Cascioli, S., Girolami, E., Bordasco, S., Vivarelli, M., Ruggiero, B., Cortis, E., Insalaco, A., Fantò, N., et al. (2010) · Rheumatology · doi:10.1093/rheumatology/keq226 · Cited by 85
Biophysical characterization of the interaction of high‐density lipoprotein (HDL) with endotoxins
Brandenburg, K., Jürgens, G., Andrä, J., Lindner, B., Koch, M. H. J., Blume, A., & Garidel, P. (2002) · European Journal of Biochemistry · doi:10.1046/j.1432-1033.2002.03333.x · Cited by 84
Yang, J., Jiang, H., Yang, J., Ding, J.-W., Chen, L., Song, L., & Zhang, X. (2009) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-009-0098-1 · Cited by 83
Toll-like receptor signalling through macromolecular protein complexes
Bryant, C. E., Symmons, M. F., & Gay, N. J. (2014) · Molecular Immunology · doi:10.1016/j.molimm.2014.06.033 · Cited by 83
Toll-like receptor 4 inhibition reduces vascular inflammation in spontaneously hypertensive rats
Bomfim, G. F., Echem, C., Martins, C. B., Costa, T. J. D., Sartoretto, S., Santos, R. A. D., Oliveira, M. A., Akamine, E. H., Fortes, Z. B., Tostes, R. C., et al. (2014) · Life Sciences · doi:10.1016/j.lfs.2014.12.001 · Cited by 82
Koulis, C., Chen, Y., Hausding, C., Ahrens, I., Kyaw, T. S., Tay, C., Allen, T. J., Jandeleit-Dahm, K. A. M., Sweet, M. J., Akira, S., et al. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.113.302407 · Cited by 81
Monnet, E., Lapeyre, G., van Poelgeest, E. P., Jacqmin, P., de Graaf, K., Reijers, J. A. A., Moerland, M., Burggraaf, J., & de Min, C. (2016) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.522 · Cited by 79
Löffler, B., Bohn, E., Hesse, B., & Kunze, H. (1985) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(85)90114-6 · Cited by 78
Seung, N. R., Park, E. J., Kim, C. W., Kim, K. H., Kim, K. J., Cho, H. J., & Park, H. R. (2007) · Journal of Cutaneous Pathology · doi:10.1111/j.1600-0560.2007.00756.x · Cited by 76
Effects of Gold Nanoparticles on Endotoxin-Induced Uveitis in Rats
Pereira, D. V., Petronilho, F., Pereira, H. R. S. B., Vuolo, F., Mina, F., Possato, J. C., Vitto, M. F., de Souza, D. R., da Silva, L., da Silva Paula, M. M., et al. (2012) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.12-10743 · Cited by 76
The Toll-Like Receptor 4-Antagonist Eritoran Reduces Murine Cardiac Hypertrophy
Ehrentraut, H., Weber, C., Ehrentraut, S., Schwederski, M., Boehm, O., Knuefermann, P., Meyer, R., & Baumgarten, G. (2011) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfr035 · Cited by 75
Toll-like receptors in systemic lupus erythematosus: potential for personalized treatment
Celhar, T., & Fairhurst, A. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00265 · Cited by 75
Foit, L., & Thaxton, C. S. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.05.021 · Cited by 75
Yang, H. Y., Kozicky, L. K., Saferali, A., Fung, S., Afacan, N. J., Cai, B., Falsafi, R., Gill, E. E., Liu, M., Kollmann, T. R., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.09.032 · Cited by 74
Self-citationSavov, J. D., Brass, D. M., Lawson, B. L., McElvania, E., Walker, J. K. L., & Schwartz, D. A. (2005) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00014.2005 · Cited by 73
Rossignol, D. P., Wasan, K. M., Choo, E., Yau, E. H., Wong, N., Rose, J., Moran, J., & Lynn, M. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.9.3233-3240.2004 · Cited by 72
Leung, P. Y., Stevens, S. L., Packard, A. E. B., Lessov, N. S., Yang, T., Conrad, V. K., van den Dungen, N. A. M., Simon, R. P., & Stenzel‐Poore, M. P. (2012) · Stroke · doi:10.1161/strokeaha.111.641522 · Cited by 71
Ziegler, G., Freyer, D., Harhausen, D., Khojasteh, U., Nietfeld, W., & Trendelenburg, G. (2010) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2010.161 · Cited by 71
Földes, G., von Haehling, S., Okonko, D. O., Jankowska, E. A., Poole-Wilson, P. A., & Anker, S. D. (2007) · International Journal of Cardiology · doi:10.1016/j.ijcard.2006.12.024 · Cited by 68
Inhibition of Mitogen-Activated Protein Kinase Signaling by Chloroquine
Weber, S. M., Chen, J., & Levitz, S. M. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.10.5303 · Cited by 67
Brea, D., Sobrino, T., Rodríguez‐Yáñez, M., Ramos‐Cabrer, P., Agulla, J., Rodríguez‐González, R., Campos, F., Blanco, M., & Castillo, J. (2011) · Clinical Immunology · doi:10.1016/j.clim.2011.02.001 · Cited by 67
Lima, C. X., Souza, D. G., Amaral, F. A., Fagundes, C. T., Rodrigues, I. P. S., Alves-Filho, J. C., Kosco‐Vilbois, M. H., Ferlin, W. G., Shang, L., Elson, G., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0132336 · Cited by 64
Protective Effects of Toll-like Receptor 4 Inhibitor Eritoran on Renal Ischemia-Reperfusion Injury
Liu, M., Gu, M., Xu, D., Lv, Q., Zhang, W., & Wu, Y. (2010) · Transplantation Proceedings · doi:10.1016/j.transproceed.2010.03.133 · Cited by 63
Dong, L., Li, H., Wang, S., & Li, Y. (2009) · Journal of Asthma · doi:10.1080/02770900802610050 · Cited by 60
Woźniacka, A. J., Lesiak, A., Boncela, J., Smolarczyk, K., McCauliffe, D. P., & Sysa‐Jędrzejowska, A. (2008) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2008.08804.x · Cited by 59
Endosomal Toll‐like receptors in clinically overt and silent autoimmunity
Clancy, R. M., Markham, A. J., & Buyon, J. P. (2015) · Immunological Reviews · doi:10.1111/imr.12383 · Cited by 49
Hydroxychloroquine potentiates Fas-mediated apoptosis of rheumatoid synoviocytes
Kim, W.-U., Yoo, S.-A., Min, S.-Y., Park, S.-H., Koh, H.-S., Song, S.-W., & Cho, C.-S. (2006) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2006.03070.x · Cited by 45
Ishibashi, M., Sayers, S., D'Armiento, J. M., Tall, A. R., & Welch, C. L. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.03.035 · Cited by 44
Hu, D., Yang, X., Xiang, Y., Li, H., Yan, H. M., Zhou, J., Caudle, Y., Zhang, X., & Yin, D. (2015) · Cellular Immunology · doi:10.1016/j.cellimm.2015.03.009 · Cited by 42
Toll-like Receptors and Atherosclerosis: Oxidized Ldl As an Endogenous Toll-like Receptor Ligand
Miller, Y. I. (2005) · Future Cardiology · doi:10.2217/14796678.1.6.785 · Cited by 39
Lynn, M., Wong, Y. N., Wheeler, J. L., Kao, R., Perdomo, C. A., Noveck, R. J., Vargas, R., D’Angelo, T., Gotzkowsky, S., McMahon, F. G., et al. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.056531 · Cited by 36
Hatterer, E., Shang, L., Simonet, P., Herren, S., Daubeuf, B., Teixeira, S., Reilly, J. H., Elson, G., Nelson, R., Gabay, C., et al. (2016) · Arthritis Research & Therapy · doi:10.1186/s13075-016-1128-5 · Cited by 35
Rodríguez-Lavado, J., Sestito, S. E., Cighetti, R., Moncayo, E. M. A., Oblak, A., Lainšček, D., Blanco, J. L. J., Fernández, J. M. G., Mellet, C. O., Jerala, R., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501182w · Cited by 32
Babazada, H., Yamashita, F., Yanamoto, S., & Hashida, M. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.09.011 · Cited by 32
Römmler, F., Hammel, M., Waldhuber, A., Müller, T., Jurk, M., Uhlmann, E., Wagner, H., Vollmer, J., & Miethke, T. (2015) · PLoS ONE · doi:10.1371/journal.pone.0116703 · Cited by 32
Liu, L., Li, Y., Hu, Z., Su, J., Huo, Y., Tan, B., Wang, X., & Liu, Y. (2013) · Nephron Experimental Nephrology · doi:10.1159/000346953 · Cited by 31
Babazada, H., Yamashita, F., & Hashida, M. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.09.015 · Cited by 30
Rossignol, D. P., Wong, N., Noveck, R. J., & Lynn, M. (2008) · Innate Immunity · doi:10.1177/1753425908099173 · Cited by 25
Guanine Modification of Inhibitory Oligonucleotides Potentiates Their Suppressive Function
Römmler, F., Jurk, M., Uhlmann, E., Hammel, M., Waldhuber, A., Pfeiffer, L., Wagner, H., Vollmer, J., & Miethke, T. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300706 · Cited by 24
Fang, D., Yang, S. S., Quan, W., Jia, H., Quan, Z., & Qu, Z. (2014) · PubMed · Cited by 24
Chen, M., Zhang, W., Xu, W., Zhang, F., & Xiong, S. (2011) · Molecular Immunology · doi:10.1016/j.molimm.2011.04.016 · Cited by 23
Tokairin, Y., Shibata, Y., Sata, M., Abe, S., Takabatake, N., Igarashi, A., Ishikawa, T., Inoue, S., & Kubota, I. (2008) · Respirology · doi:10.1111/j.1440-1843.2007.01229.x · Cited by 21
Rodrigues, F. L., Silva, L. E. V., Hott, S. C., Bomfim, G. F., Silva, C. A. A., Fazan, R., Resstel, L. B. M., Tostes, R. C., & Carneiro, F. S. (2015) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00150.2014 · Cited by 20
Khan, A.-M., Li, M., Abdulnour‐Nakhoul, S. M., Maderdrut, J. L., Simon, E. E., & Batuman, V. (2012) · Peptides · doi:10.1016/j.peptides.2012.09.023 · Cited by 18
Lin, P. J. C., & Tam, Y. K. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.108 · Cited by 18
Bergt, S., Wagner, N., Heidrich, M., Butschkau, A., Nöldge-Schomburg, G. E. F., Vollmar, B., & Roesner, J. P. (2013) · Shock · doi:10.1097/shk.0000000000000029 · Cited by 11
Cited by
Obesity, Insulin Resistance, and Type 2 Diabetes: Associations and Therapeutic Implications
Wondmkun, Y. T. (2020) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s275898 · Cited by 706
Design of therapeutic biomaterials to control inflammation
Tu, Z., Zhong, Y., Hu, H., Shao, D., Haag, R., Schirner, M., Lee, J., Sullenger, B., & Leong, K. W. (2022) · Nature Reviews Materials · doi:10.1038/s41578-022-00426-z · Cited by 513
Sameer, A. S., & Nissar, S. (2021) · BioMed Research International · doi:10.1155/2021/1157023 · Cited by 323
Ball, D. H., Al-Riyami, L., Harnett, W., & Harnett, M. M. (2018) · Scientific Reports · doi:10.1038/s41598-018-22716-9 · Cited by 197
Nanotools for Sepsis Diagnosis and Treatment
Papafilippou, L., Claxton, A., Dark, P., Kostarelos, K., & Hadjidemetriou, M. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202001378 · Cited by 118
Metadata
- Authors
- Gao, W., Xiong, Y., Li, Q., & Yang, H.
- Venue
- Frontiers in Physiology
- Publisher
- Frontiers Media SA
- Published
- 2017-07-19
- Volume
- 8
- Pages
- 508-508
- ISSN
- 1664-042X (ISSN-L)
- OpenAlex
- W2737868829
- Cited by
- 353
- References
- 175
- FWCI
- 13.19
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
